公开(公告)号：US20230390343A1

公开(公告)日：2023-12-07

申请号：US18232433

申请日：2023-08-10

Applicant: Seed Health, Inc.

Inventor： Sheri Simmons ,  Tye Jensen ,  Joseph E. Kovarik

IPC: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K38/17

CPC classification number: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K38/1709 ,  A61K38/1758 ,  A61K2035/11

Abstract: A method to reduce the likelihood of a dysbiosis of the vaginal microbiome in an individual employing a probiotic method and composition for maintaining a healthy vaginal microbiome, with particular embodiments including a bacterial formulation of at least two live bacteria selected from the group consisting of L. reuteri, L johnsonii and L. crispatus, and at least one prebiotic having glycogen as a component thereof. The bacterial formulation is administered to an individual's vagina in an amount sufficient for the bacterial formulation to generate an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists, thereby reducing inflammation in the individual's vagina. Certain embodiments include increasing the production of SCFAs in the individual's gut microbiome, while reducing the production of SCFAs in the individual's vagina and introducing ammonia oxidizing microorganisms to the individual's vagina.

公开(公告)号：US20230241129A1

公开(公告)日：2023-08-03

申请号：US18130946

申请日：2023-04-05

Applicant: Seed Health, Inc.

Inventor： Sheri Simmons ,  Tye Jensen ,  Joseph E. Kovarik

IPC: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/17

CPC classification number: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/1758 ,  A61K38/1709 ,  A61K2035/11

Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria, postbiotics, metabolites and other microbe components to foster the growth and maintenance of a healthy skin microbiome. One embodiment includes a topical application of Lactobacillus Crispatus to ameliorate skin barrier damage and inflammation using unique combinations of probiotics, prebiotics, postbiotics, and other skin-beneficial ingredients, effectively treating inflammatory skin diseases, such as atopic dermatitis, psoriasis and acne, through the production of tryptophan metabolites that act as AHR agonists.

公开(公告)号：US20220378853A1

公开(公告)日：2022-12-01

申请号：US17854422

申请日：2022-06-30

Applicant: SEED HEALTH, INC.

Inventor： Joseph E. Kovarik

IPC: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/17

Abstract: The methods described herein are for treating infections in individuals having cancer and who are receiving cancer immunotherapy, preferably employing a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and thereafter, administering an immune checkpoint inhibitor thereto. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa, Klebsiella bacteria, Staphylococcus aureus; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; Clostridium; Neisseria gonnorrhoea; Acinetobacter baumannii; and Campylobacter bacteria and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Enterococcus, Fusobacterium, Coprococcus, LactoBacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, and F. prausnitzii. The CRISPR system may include Cas9, Cpf1 and Cas3, and may be delivered using a bacteriophage.

公开(公告)号：US20220296655A1

公开(公告)日：2022-09-22

申请号：US17835204

申请日：2022-06-08

Applicant: SEED HEALTH, INC.

Inventor： Joseph E. Kovarik

IPC: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/17

Abstract: A method for reducing the likelihood of an individual developing colorectal cancer includes the use of a CRISPR system to selectively kill pathogenic bacteria, such as Klebsiella and E. coli, within the individual. Preferrably, the growth of a beneficial bacteria, such as Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, and Streptococcus bacteria, is also enhanced. Reduction of certain virulence factors, such as colibactin, using a CRISPR system, as well the employment of immune checkpoint inhibitors, is effective in treating individuals with cancer and who suffer from a chronic infectious disease.

公开(公告)号：US12246043B2

公开(公告)日：2025-03-11

申请号：US18535722

申请日：2023-12-11

Applicant: Seed Health, Inc.

Inventor： Tye Jensen ,  Joseph E. Kovarik ,  Raja Dhir

IPC: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K35/00 ,  A61K35/741 ,  A61K35/745 ,  A61K35/747 ,  A61K38/17 ,  C12N1/20

Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome. Embodiments include methods for treating an individual suffering from acne valgaris by topically administering a composition that includes live bacteria selected from the group consisting of L. reuteri, L. johnsonii, L. crispatus, C. acnes, and Nitrosomonas eutropha, that have been modified by using a using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system to reduce the production of a virulence factor of the bacteria.

公开(公告)号：US12005085B2

公开(公告)日：2024-06-11

申请号：US18232433

申请日：2023-08-10

Applicant: Seed Health, Inc.

Inventor： Sheri Simmons ,  Tye Jensen ,  Joseph E. Kovarik

IPC: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K35/00 ,  A61K38/17

CPC classification number: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K38/1709 ,  A61K38/1758 ,  A61K2035/11

Abstract: A method to reduce the likelihood of a dysbiosis of the vaginal microbiome in an individual employing a probiotic method and composition for maintaining a healthy vaginal microbiome, with particular embodiments including a bacterial formulation of at least two live bacteria selected from the group consisting of L. reuteri, L johnsonii and L. crispatus, and at least one prebiotic having glycogen as a component thereof. The bacterial formulation is administered to an individual's vagina in an amount sufficient for the bacterial formulation to generate an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists, thereby reducing inflammation in the individual's vagina. Certain embodiments include increasing the production of SCFAs in the individual's gut microbiome, while reducing the production of SCFAs in the individual's vagina and introducing ammonia oxidizing microorganisms to the individual's vagina.

公开(公告)号：US11998574B2

公开(公告)日：2024-06-04

申请号：US18235686

申请日：2023-08-18

Applicant: Seed Health, Inc.

Inventor： Sheri Simmons ,  Tye Jensen ,  Raja Dhir ,  Joseph E. Kovarik

IPC: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K35/00 ,  A61K38/17

CPC classification number: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K38/1709 ,  A61K38/1758 ,  A61K2035/11

Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria, postbiotics, metabolites and other microbe components to foster the growth and maintenance of a healthy skin microbiome. One embodiment includes a topical application of Lactobacillus crispatus to ameliorate skin barrier damage and inflammation using unique combinations of probiotics, prebiotics, postbiotics, and other skin-beneficial ingredients, effectively treating inflammatory skin diseases, such as atopic dermatitis, psoriasis and acne, through the production of tryptophan metabolites that act as AHR agonists.

公开(公告)号：US11951139B2

公开(公告)日：2024-04-09

申请号：US17893384

申请日：2022-08-23

Applicant: Seed Health, Inc.

Inventor： Joseph E. Kovarik

IPC: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K35/00 ,  A61K38/17

CPC classification number: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K38/1709 ,  A61K38/1758 ,  A61K2035/11

Abstract: Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individual's microbiome to reduce the likelihood of osteoporosis.

公开(公告)号：US20230172995A9

公开(公告)日：2023-06-08

申请号：US17694775

申请日：2022-03-15

Applicant: Seed Health, Inc.

Inventor： Joseph E. Kovarik

IPC: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/17

CPC classification number: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/1758 ,  A61K38/1709 ,  A61K2035/11

Abstract: A method for reducing the likelihood of developing depression in an individual involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of bacterial species able to make small chain fatty acids, and preferably butyrate, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. The individual's gut microbiome is modified to reduce the number of undesired bacteria and to increase the number of beneficial bacteria. Bacteria are preferably modified to remove one or more virulence facts or alternatively to produce increased amounts of SCFA's, such as butyrate. Beneficial bacteria may be encapsulated in a frangible enclosure to ensure they arrive in an individual's body while still viable, e.g. such as being first released in the lower gut rather than being exposed to the harsh conditions of an individual's stomach. In other embodiments, a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii is administered. Other embodiments include the administration of a bacterial formulation comprising at least one of Coprococcus, Roseburia, Bifidobacterium, Faecalibacterium prausnitzii and L. casei to treat depression.

公开(公告)号：US20220296500A1

公开(公告)日：2022-09-22

申请号：US17836079

申请日：2022-06-09

Applicant: Seed Health, Inc.

Inventor： Joseph E. Kovarik

IPC: A61K9/00 ,  A61K9/70 ,  A61K31/047 ,  A61K35/744 ,  A61K49/00 ,  A61K35/74 ,  A61K45/06 ,  A61K35/741 ,  A61F5/56

Abstract: A method and system to prevent sore throat infections in humans includes the administration of an active ingredient to a site on the mucus membranes of the throat of a human that inhibits adherence and promotes desorption of S. pyogenes to soft tissue surfaces, such as the pharyngeal and oral mucosa of a human. A mucoadhesive strip having a surface topography that resists bioadhesion of undesired bacteria that are typically present in a human's mouth is preferably employed and that has one or more encapsulated agents selected from the group consisting of an antibiotic; lactic acid bacteria; S. pyogenes modified by a CRISPR-Cas system to reduce one or more virulence factors; and a breath mint solution.